Background: In response to COVID-19, the UK National Health Service (NHS) extended influenza vaccination in 50- to 64-year-olds from at-risk only to all in this age group for the 2020/21 season. The objective of this research is to determine the cost-effectiveness of continuing to vaccinate all with a quadrivalent cell-based vaccine (QIVc) compared to returning to an at-risk only policy after the pandemic resolves.
Methods: A dynamic transmission model, calibrated to match infection data from the UK, was used to estimate the clinical and economic impact of vaccination across 10 influenza seasons. The base case effectiveness of QIVc was 63.9% and the list price was GBP 9.94.
Results: Vaccinating 50% of all 50- to 64-year-olds with QIVc reduced the average annual number of clinical infections (-682,000), hospitalizations (-5800) and deaths (-740) in the UK. The base case incremental cost per quality-adjusted life-year gained (ICER) of all compared to at-risk only was GBP6000 (NHS perspective). When the cost of lost productivity was considered, vaccinating all 50- to 64-year-olds with QIVc became cost-saving.
Conclusion: Vaccinating all 50- to 64-year-olds with QIVc is likely to be cost-effective. The NHS should consider continuing this policy in future seasons.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228189 | PMC |
| http://dx.doi.org/10.3390/vaccines9060598 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Incidence, healthcare and out-of-pocket costs, and mortality of infection among US adults aged 18 to 64 years.
Antimicrob Steward Healthc Epidemiol
December 2024
Departments of Medicine and Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Objective: To estimate incidence and healthcare costs and mortality associated with infection (CDI) among adults <65 years old.
Design: Retrospective cohort study.
Patients: First CDI episodes among commercially insured US patients 18-64 years old were identified from a large claims database.
Member Adherence to a Health Insurer-Sponsored Gap Closure Program Using Multi-Target Stool DNA Test for Colorectal Cancer Screening.
J Prim Care Community Health
December 2024
Exact Sciences Corporation, Madison, WI, USA.
Objectives: To describe member adherence to a mail-based, health insurer-sponsored gap closure program for colorectal cancer (CRC) screening using multi-target stool DNA (mt-sDNA; Cologuard) tests.
Methods: Combined patient data from Exact Sciences Laboratories LLC and data from mass-mailed mt-sDNA orders placed by a large Medicare Advantage Insurance Plan were analyzed (03/01/2023-06/30/2023). Adherence and time to test return were the primary and secondary outcomes, respectively.
Emergence of terbinafine-resistant in Ontario, Canada, 2014-2023.
J Clin Microbiol
November 2024
Public Health Ontario, Toronto, Ontario, Canada.
Article Synopsis
- - An emerging fungal pathogen is causing a rise in difficult-to-treat dermatophytosis cases, especially in India, with some infections spreading globally, raising public health concerns.
- - In Ontario, Canada, there has been a notable increase in cases between 2014 and 2023, particularly affecting adults aged 20 to 64, and these cases are genetically similar to those found in other countries.
- - The majority of isolates in Ontario show resistance to terbinafine, a common treatment, highlighting the urgent need for better detection methods and public health awareness to control future outbreaks and treat infections effectively.
Nationwide trends in the use of ADHD medications in the period 2006-2022: a study from the Norwegian prescription database.
BMC Psychiatry
November 2024
Department of Chronic Diseases, Norwegian Institute of Public Health, Postbox 222 Skøyen, Oslo, 0213, Norway.
Background: The use of medication for Attention-Deficit/Hyperactivity Disorder (ADHD) increased globally throughout the early 2000s. This study examine trends in prevalences and incidences of medication use in Norway from 2006 to 2022.
Methods: Data from the Norwegian Prescription Database were used to present one-year-prevalence and incidence rates of ADHD medication (ATC-group N06BA and C02AC02) for the overall population (ages 6-64) and within sex and age subgroups of children (ages 6-17) and adults (ages 18-64).
Age-specific performance of human papillomavirus E6/E7 mRNA assay versus cytology for primary cervical cancer screening and triage: community-based screening in China.
Front Cell Infect Microbiol
September 2024
Department of Neurosurgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China.
Background: In the general population, primary human papillomavirus (HPV) testing is advocated for cervical cancer (CC) screening. HPV E6/E7 mRNA (Aptima HPV, AHPV) assays have garnered considerable traction due to their higher specificity when compared with HPV DNA assays. Here, we investigated age-specific primary AHPV screening assays and different triage strategies versus cytology to identify the best approach.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!